




# PHARMACEUTICAL 2021

Regen BioPharma Inc  
Rank 361 of 402





# PHARMACEUTICAL 2021

Regen BioPharma Inc  
Rank 361 of 402

The relative strengths and weaknesses of Regen BioPharma Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Regen BioPharma Inc compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 153% points. The greatest weakness of Regen BioPharma Inc is the variable Liabilities, Current, reducing the Economic Capital Ratio by 457% points.

The company's Economic Capital Ratio, given in the ranking table, is -243%, being 290% points below the market average of 47%.

Input Variable	Value in 1000 USD
Assets, Current	103
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	7,458
Liabilities, Non-Current	0
Other Assets	20
Other Compr. Net Income	0
Other Expenses	56
Other Liabilities	0
Other Net Income	3,624
Other Revenues	110
Property and Equipment	0
Research and Development	13
Selling, General and Administrative Expense	250

Output Variable	Value in 1000 USD
Assets	123
Liabilities	7,458
Expenses	319
Revenues	110
Stockholders Equity	-7,335
Net Income	3,414
Comprehensive Net Income	3,414
Economic Capital Ratio	-243%